Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Chetan Bettegowda

Neurosurgery
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Distinguished in Embryonal Tumor with Multilayered Rosettes
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chetan Bettegowda is a Neurosurgery provider in Baltimore, Maryland. Dr. Bettegowda is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression. Dr. Bettegowda is currently accepting new patients.

His clinical research consists of co-authoring 385 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Neurosurgery
Licenses
Neurological Surgery in MD
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Kannada
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287
Other Locations
JOHNS HOPKINS UNIVERSITY
601 N Caroline St, Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Enrollment Status: Terminated
Publish Date: February 08, 2024
Intervention Type: Drug
Study Drug: BGB 324
Study Phase: Early Phase 1
Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection
Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug, Other
Study Drug: Prazosin
Study Phase: Phase 2
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

384 Total Publications

Surgical Adverse Events for Primary Tumors of the Spine and Their Impact on Outcomes: An Observational Study From the Primary Tumors Research and Outcomes Network: Corrigendum.
Surgical Adverse Events for Primary Tumors of the Spine and Their Impact on Outcomes: An Observational Study From the Primary Tumors Research and Outcomes Network: Corrigendum.
Journal: Neurosurgery
Published: October 17, 2025
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Jon Weingart
Neurosurgery
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Jon Weingart
Neurosurgery

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (0.1 miles away)
410-502-4340
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jon Weingart is a Neurosurgery provider in Baltimore, Maryland. Dr. Weingart is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Gary L. Gallia
Neurosurgery
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Gary L. Gallia
Neurosurgery

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (0.1 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Gallia is a Neurosurgery provider in Baltimore, Maryland. Dr. Gallia is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Olfactory Neuroblastoma, Chordoma, Pituitary Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Awake Craniotomy. Dr. Gallia is currently accepting new patients.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Graeme F. Woodworth
Neurosurgery
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Graeme F. Woodworth
Neurosurgery

University Of Maryland Neurosurgery Associates P A

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-6034
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Graeme Woodworth is a Neurosurgery provider in Baltimore, Maryland. Dr. Woodworth is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Woodworth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bettegowda's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 17 Distinguished Conditions
View All 14 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile